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Summary  
C-X-C chemokine receptor (CXCR)3 and its interferon(IFN)γ-dependent chemokines 
(CXCL10, CXCL9, CXCL11) are implicated in the immune-pathogenesis of 
autoimmune thyroiditis (AT), Graves disease (GD) and Graves Ophthalmopathy 
(GO). In tissue, recruited Th1 lymphocytes produce IFNγ, enhancing the tissue 
secretion of IFNγ-inducible chemokines, initiating and perpetuating the autoimmune 
process. Patients with AT (with hypothyroidism), and with GO and GD, particularly 
in the active phase, have high IFNγ-inducible chemokines. Peroxisome proliferator-
activated receptor(PPAR)γ or -α agonists and methimazole exert an immune-
modulation on CXCR3 chemokines in AT, GD and GO. Other studies are ongoing to 
evaluate new molecules acting as antagonists of CXCR3, or blocking CXCL10, in 
Hashimoto thyroiditis (HT), GD and GO.  
Recently, novel molecules targeting the various agents involved in the pathogenesis of 
GO, such as rituximab, have been proposed as an alternative to corticosteroids. 
However, randomized and controlled studies are needed to generalize these 
interesting results. 
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EXPERT COMMENTARY 
Many progresses have been made in the knowledge of the immune-pathogenesis of 
autoimmune thyroid disorders. Th1 lymphocytes are very important in the 
autoimmune process, such as IFNγ and the IFNγ dependent chemokines. CXCR3 and 
its IFNγ dependent chemokines (CXCL10, CXCL9, CXCL11) are important in the 
immune-pathogenesis of autoimmune thyroiditis (AT), Graves Ophthalmopathy (GO), 
and Graves disease (GD). Under the stimulation of IFNγ, the IFNγ-induced 
chemokines are secreted by thyrocytes, orbital fibroblasts or preadipocytes. Th1 
lymphocytes are recruited in tissues, hence IFNγ is further produced, enhancing the 
tissue secretion of IFNγ-inducible chemokines, perpetuating the autoimmune process. 
The presence of elevated IFNγ-inducible chemokines levels in peripheral fluids is a 
marker of Th1 orientated immune-response. High circulating levels of IFNγ-inducible 
chemokines have been shown in patients with AT (with hypothyroidism), and in GD 
and GO patients (in the active phase).   
Attempts have been made to modulate the autoimmune process in autoimmune 
thyroid diseases (AITD). Peroxisome proliferator-activated receptor (PPAR)γ or -α 
agonists exert a modulatory role on CXCR3 chemokines in autoimmune thyroid 
disorders. Also methimazole has as immune-modulatory effect on CXCR3 and its 
chemokines in GD. Cortiscosteroids have been shown to inhibit the production of 
IFNγ and the IFNγ dependent chemokines in AITD, too. Other studies are ongoing to 
evaluate the use of new molecules antagonists of CXCR3, or that block CXCL10, in 
Hashimoto thyroiditis (HT), GD and GO. 
In recent years, novel molecules which target the different agents involved in the 
immune-pathogenesis of GO have been proposed as an alternative to corticosteroids. 
A randomized trial with rituximab suggests good efficacy in patients with active GO. 
However discordant results have been reported, too. Promising results have been 
observed with small antagonists of TSH-R molecules (that interact with the receptor 
in thyrocytes and fibroblasts), with the anti-IGF-1 receptor monoclonal antibody 
teprotumumab, and with tocilizumab (an antibody anti-soluble IL-6 receptor) in GO. 
However, randomized and controlled studies are needed to generalize these 
interesting results. 
 Five-year view: 
 
Studies are evaluating the use of new molecules antagonists of CXCR3, or that block 
CXCL10, in HT, GD and GO. 
The possibility that new selective PPARγ or PPARα agonists exert anti-inflammatory 
action, without undesirable secondary effects, in HT, GD and GO, will be explored. 
Small antagonists of TSH-R molecules (that interact with the receptor in thyrocytes 
and fibroblasts), which have been shown effective in vitro, will be tested for the 
therapy of GD and GO.  
The results of a randomized trial show the efficacy of rituximab in patients with active 
GO, when compared with intravenous methylprednisolone. However, because of 
other discordant results, other studies are needed to evaluate rituximab in GO patients 
with different phenotype and clinical history. 
Teprotumumab, a monoclonal anti-IGF-1R antibody, is evaluated in a randomized 
controlled trial in GO.  
On the base of the results of a recent study with tocilizumab (monoclonal antibody 
anti-soluble-IL-6 receptor) that have shown efficacy in inactivating GO, randomized 
studies will be conducted.   
 
Key issues 
1- Many progresses have been made in the knowledge of the immune-pathogenesis of 
autoimmune thyroid disorders. Th1 lymphocytes are very important in the 
pathogenesis of AITD.  
2- IFNγ, IFNγ dependent chemokines (CXCL9, CXCL10, CXCL11) and their receptor 
(CXCR3) are important in the pathogenesis of AT, GD and GO. 
3- High circulating levels of IFNγ-inducible chemokines have been shown in patients 
with AT (with hypothyroidism), and in GD or GO patients (in the active phase).   
4- PPARγ or -α agonists, MMI and corticosteroids have been shown to exert a 
modulatory role on CXCR3 chemokines in AT, GO and GD.  
5- Studies are evaluating the use of new molecules antagonists of CXCR3, or that 
block CXCL10, in HT, GD and GO. 
6- The results of a randomized trial show the efficacy of rituximab in patients with 
active GO. However, because of other discordant results, other studies are needed. 
7- Small antagonists of TSH-R molecules (that interact with the receptor in thyrocytes 
and fibroblasts), which has been shown effective in vitro, will be tested for the 
therapy of GO and GD.  
8- Teprotumumab, a monoclonal anti-IGF-1R antibody, is evaluated in a randomized 
trial in GO.  
9- On the base of the results of a recent study with tocilizumab (a monoclonal anti-
soluble-IL-6 receptor) that have shown efficacy in inactivating GO, randomized 
studies will be conducted.   
Introduction 
 
The prevalence of autoimmune thyroid diseases (AITD) is about 5% [1]. The most 
common AITD are Hashimoto thyroiditis (HT) or Graves disease (GD), clinically 
characterized by hypothyroidism and thyrotoxicosis, respectively [2].  
An increased incidence of AITD have been shown [3] from the mid-1990s, associated 
with a progressive reduction in age at presentation and female/male ratio. 
The reasons of the change of AITD epidemiology are not known. Rizzo et al. [3], 
that collected 8397 fine needle aspiration cytology (FNAC) between 1988 and 
2007, demonstrated that the frequency of HT increased from 1996 (+350% over 
1995). Only 1 man was present till 1995, but there were 22 men in 2005-2007. These 
results suggested that only environmental changes are able to explain the strong 
incidence modifications occurred in that short lapse of time.  
Many studies have demonstrated that: a) the risk for women is higher than for men 
(5/1, female/male); b) the hypothyroidism linked to HT is more frequent with aging; 
c) the frequency of antithyroid antibodies is increasing with age; d) a significant 
geographic variability in the prevalence of AITD is known; e) the prevalence of AITD 
is higher in iodine-sufficient areas than iodine-deficient ones [4].  
Other environmental possible risk factors shown by recent studies include 
vitamin D deficiency, age and of course sex [5].  
AITD are usually of low severity, but in some cases are able to affect importantly the 
quality-of-life (QOL), and cause substantial medical costs. Cognitive function is one 
of the most important parameter of the QOL and the available literature about this has 
been reviewed [6], reporting conflicting results on the association between subclinical 
hypothyroidism and cognitive and health related QOL (HRQOL) impairment. 
However, a lowering in HRQOL in patients with thyroid autoimmune diseases, 
regardless of hypothyroidism or hyperthyroidism, has been shown in most of the 
studies [6].  
Graves Ophthalmopathy (GO) is a debilitative condition causing facial disfigurement 
and impairing visual function, with a negative impact on patients' employment, and 
psychosocial function [7], characterized by inflammation in the orbital tissues (eye 
muscles and connective tissue), and tissue remodeling owing to an altered production 
of preadipocytic fibroblasts and increased adipogenesis [8].	  The supposed mechanism 
of GO pathogenesis is an immunological cross-reactivity among antigens expressed 
into the thyroid or the orbit, in which the coexpression of thyroid-stimulating 
hormone receptor (TSH-R) and insulin growth factor-1 receptor (IGF-1R) in orbital 
fibroblasts has been shown to be determinant [9].	   	  
However another study demonstrated the existence of IGF1R-antibodies in 
humans but do not support the hypothesis that the IGF1R-antibodies contribute 
to GO pathogenesis [10].  
Furthermore, euthyroid GD is an important model for ophthalmopathy in the 
absence of thyroid autoimmunity. Recent studies have shown that TSH receptor 
antibodies measured in the Thyroid-Stimulating Immunoglobulin (TSI) assay 
was not detected in any patient with euthyroid GD defined as ophthalmopathy, 
suggesting that these antibodies might not be the cause of ophthalmopathy in GD 
either [11]. 	  
Other candidate antigens in GO are collagen XIII, flavoprotein sub-unit SDH 
and particularly calsequestrin although antibodies and T cell reactivity against 
these proteins are likely secondary to the disease [12]. 
According to epidemiological data, the mechanisms that cause the autoimmune attack 
in the thyroid are linked to an interaction among environmental triggers and genetic 
susceptibility, causing the failure of immune-tolerance and the development of the 
autoimmune disease [4].  
AITD are predominant in female gender, and estrogens seem to be important in the 
appearance of AITD, such as the immunological modifications associated with 
pregnancy and postpartum. It has been hypothesized that the presence of cells from 
one subject to another genetically distinct (microchimerism) during pregnancy, could 
be an important endogenous factors linked to AITD [13].  
Environmental risk factors (such as radiation, iodine, drugs, smoking, stress and 
viruses) have been identified, that are able to activate the development of AITD in 
susceptible individuals [4]. The prevalence of AITD is higher in areas with iodine 
sufficiency, and iodine supplementation is associated with an increase of AITD 
(overall in areas previously iodine deficient) [14]. 	  
Cigarette smoking is a risk factor for GD and GO, while it decreases the risk of overt 
hypothyroidism [15].  
Specific selenoproteins are expressed by the thyroid tissue, and selenium deficiency is 
important in the development of thyroid autoimmunity, while selenium 
supplementation protects from AITD [16].  
Many studies have evaluated the importance of viruses in the occurrence of AITD, 
reporting controversial results [17].  
However more recently, the association between HCV infection and AITD has been 
reported in adults, and in children [18-20].  
A high frequency of autoimmune thyroiditis (AT) and hypothyroidism, in the female 
gender, in the presence of high anti-thyroperoxidase (AbTPO) levels, characterizes 
the thyroid disorders observed in HCV infection [4]. Moreover, an increased 
prevalence of serum AbTPO, and/or anti-thyroglobulin antibodies (AbTg), and 
subclinical hypothyroidism have been shown in patients with mixed cryoglobulinemia 
and hepatitis C (MC+HCV) [21, 22]. More recently, it has been demonstrated the 
presence of HCV in the thyroid tissue in HCV patients, and that HCV is able to infect 
human thyroid cells (ML1), suggesting that HCV infection of thyrocytes is 
determinant in the association between HCV and AITD [23].  
It has been reported an association of AITD with interferon (IFN)-α therapy in HCV 
patients: in fact, 40% of HCV patients present thyroid disorders (destructive 
thyroiditis, or AT) during IFN-α therapy. IFN-α induces thyroiditis through direct 
toxic effects on the thyroid cells, or immune stimulation. However, HCV and IFN-α 
could synergistically cause AITD [24].  
Genetic susceptibility to AITD has been evidenced by: 1- the familial clustering of the 
disease (25% of AITD in siblings of AITD patients); 2- sibling risk ratio of 
approximately 17 in AITD; 3- a higher prevalence of thyroid autoantibodies in 
siblings of AITD patients. Furthermore, a concordance rate for AITD of 0.5 for 
monozygotic, and the heritability of GD of about 80%, have been shown by twin 
studies, while that of thyroid autoantibodies is approximately 70% [13].  
Various genes are significantly associated with the risk of AITD and the presence of 
thyroid antibodies, and among them about 70% (of the ones whose function is known) 
are involved in T cells function. This suggests the importance of T lymphocytes in the 
pathogenesis of AITD [25].  
In fact, chronic AT may occur also in the absence of circulating anti-thyroid 
antibodies [26]. 
A recent publication shows that two single neucleotide polymorphisms in the 
calsequestrin gene are linked to ophthalmopathy in patients with GD [27]. 
An association between AITD and other autoimmune disorders has been reported.	  
Polyglandular autoimmune syndromes are organ specific autoimmune disorders 
characterized by failure of several endocrine glands and non endocrine organs, caused 
by an autoimmune attack [28].  
Type 1 diabetes, GD, HT, Addison's disease, vitiligo, alopecia, hypogonadism were 
shown respectively in 61%, 33%, 33%, 19%, 20%, 6%, and 5%, of these patients. A 
common genetic susceptibility is the base of the association of AITD and Type 1 
diabetes in these patients. Many studies suggest that patients with AITD and 
polyglandular autoimmune syndromes should be followed regularly, in order to 
evaluate the appearance of new circulating organ-specific antibodies, and of other 
clinical diseases [29].	   	  
Patients with systemic rheumatological diseases [Sjögren’s syndrome (SS), 
scleroderma, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), 
sarcoidosis] show frequently thyroid autoantibodies and dyfunctions [4, 30-32]. Also 
in these patients the presence of a common genetic susceptibility have been 
demonstrated: for example in Caucasian patients the histocompatibility antigens 
(HLA) of the haplotypes HLA-B8 and DR3 are associated both with AITD, such as 
with primary SS [33]. In SLE patients: a- the association with AITD has been 
reported in 5q14.3-q15 (the major locus of susceptibility for SLE, found in AITD, 
too) patients; b- the frequency of HLA-B8 and DR3 is significantly higher in patients 
with AITD and SLE than in controls [34]. Also environmental factors could be 
important in the association of AITD and systemic autoimmune disorders [4].  
Several studies have shown an association of AITD with papillary thyroid cancer 
(PTC) [35]. The link of the association between PTC and AITD has been suggested to 
be the increase of TSH (that is a growth factor for PTC) in HT, or the autoimmune 
inflammatory process, in different studies. In a recent report of 13738 patients [36], 
the frequency of PTC, TSH levels and thyroid autoantibodies were evaluated. The 
results showed the frequency of PTC was mainly associated with the increased TSH 
levels [36] in HT. On the contrary, other studies have found that both thyroid 
autoimmunity, and a high TSH, are independent risk factors for PTC [37]. The 
increased frequency of PTC in AITD patients is clinically important; in fact, about 
20% of PTC patients may develop an aggressive disease [35].	  
On the base of the above mentioned studies, it is suggested that AITD patients should 
be followed for the appearance of thyroid dysfunctions, or nodules, or other systemic 
autoimmune disorders during the disease course [4].  	  
Th1 chemokines in HT 
 
During AITD, inflammatory immune-cells infiltrate the thyroid and secrete 
autoantibodies to thyroglobulin and thyroperoxidase, leading to the destruction of the 
follicles and the appearance of hypothyroidism. Th1 lymphocytes, as IFNγ  and the 
IFNγ  dependent chemokines (CXCL9, -10, -11), play a critical role in the 
autoimmune process [38-43].  
In C57BL6 transgenic mice (that aberrantly express IFNγ under the control of the 
thyroglobulin promoter) it has been shown an increased expression of CXCL10 [44].  
CXCL10 is not produced in normal human thyrocytes; however, the CXCL10 dose-
dependent secretion is induced by IFNγ in thyroid follicular cells, and the co-
stimulation with IFNγ+tumor necrosis factor (TNF)α induces a synergistic CXCL10 
release, in comparison with IFNγ alone [45]. 
Indeed, increased levels of CXCL10 were found (by immunohystochemistry) in 
thyroid tissues from AITD [38]. Thyroid follicular cells in HT expressed CXCL10, 
suggesting the local production of Th1 chemokines is important in the recruitment of 
inflammatory cells into the thyroid gland [38]. In patients with newly diagnosed AT, 
circulating CXCL10 were significantly higher, than in controls; overall in those 
patients with hypothyroidism, or a hypoechoic ultrasonographic pattern [4], 
suggesting CXCL10 is a marker of a more aggressive thyroid autoimmune process, 
leading to the destruction of the thyroid gland [4].  
The above mentioned results underline the importance of the Th1 immune attack in 
the early phase of AITD, while other studies exclude the involvement of the Th2 
chemokines [such as (C-C motif) ligand 2 (CCL2) chemokine] [4].  
Furthermore, CXCL9, -10, -11, co-stimulate the IFNγ production by (CD)4+ T-cells, 
producing a positive cytokine/chemokine feed-back loop, that reiterates the Th1-
immune response and enhances the inflammatory process linked to IFNγ [46].  
To sum up, thyroid cells under the stimulation by cytokines (IFNγ, TNFα) produce 
CXCL10, that induces the Th1 lymphocytes migration into the thyroid, which secrete 
more cytokines, stimulating a further chemokine release by the follicular cells, 
initiating and perpetuating the autoimmune response [47]. 
	  
IFNγ  dependent chemokines in GD 
 
TSH-R stimulating autoantibodies are pathogenetic of GD [48], and GD is an 
autoantibody-mediated, Th2-dominant disease. However, a Th1-immune 
predominance is present at the beginning of GD [4].  
IFNγ dependent chemokines, in GD, are expressed by thyrocytes and in infiltrating 
inflammatory cells and endothelial cells [4], and the C-X-C chemokine receptor 
(CXCR)3 has been demonstrated in endothelial and inflammatory cells. 
In the early GD phase the secretion of CXCL10 by follicular cells induces the 
recruitment of Th1 lymphocytes into the thyroid [49]. IFNγ dependent chemokines 
secreted into the thyroid gland enter the circulation, and serum levels of these 
chemokines are high in GD patients [4].	  Circulating IFNγ dependent chemokines are 
higher in hyperthyroid GD, than euthyroid or hypothyroid patients, and methimazole 
(MMI) therapy determines a decrease of them. Newly diagnosed GD patients had 
similar circulating CXCL10, than relapsed GD patients, demonstrating that high 
serum levels of these chemokines are associated with the active phase of GD (both at 
the beginning, such as in relapses) [50].  
Also in peripheral blood lymphocytes the Th1 profile predominates (on the Th2) in 
GD patients in the early active phase, while a Th1 to Th2 switch is observed after the 
beginning of MMI therapy [51]. 	  
Human GD thyrocytes (in primary cultures) do not secrete CXCL10; however, IFNγ 
is able to induce a dose-dependent chemokine secretion; also in this case, the co-
stimulation with IFNγ plus TNFα of thyrocytes induces a potent synergistic CXCL10 
release (with respect to IFNγ alone) [45].	   	  
Other studies have shown the severity of GD can be predicted by CXCL10 
polymorphism [52], and that CXCL10 could not decline during the remission phase 
[53].  
The findings that, in GD patients, circulating CXCL10 levels decline after radioiodine 
ablation, or near-total thyroidectomy, suggest the chemokine is secreted mainly in the 
thyroid gland in AITD patients [54-56].  	  
IFNγ  dependent chemokines, or CXCR3, as therapeutic targets in HT and GD 
 
Small antagonists, neutralizing monoclonal antibodies, modified chemokines, and 
binding proteins can be used to interfere with chemokines or CXCR3 function [4]. 
The pharmacological use of such molecules in animal models have demonstrated 
some problems, and primary human cell cultures are used to evaluate the modulating 
ability of these drugs on the cytokine-induced chemokine production [4].	   	  
Peroxisome proliferator-activated receptor (PPAR)γ are implicated in the modulation 
of IFNγ-induced chemokine expression in human autoimmune disorders, and in the 
down-regulation of inflammatory responses. Many papers have critically reviewed the 
evidences of the anti-inflammatory action of PPAR-agonists [57].	   PPARγ agonists 
reduce the recruitment of activated T lymphocytes at sites of Th1-mediated 
inflammation [58].	   	  
PPARγ activator rosiglitazone (0.1–10 µM) reduces dose-dependently the secretion of 
IFNγ dependent chemokines (induced by IFNγ+TNFα) in thyrocytes, suggesting 
PPARγ-agonists modulate CXCR3 chemokines [45, 47]. 	  
PPARα ligands have shown therapeutic action in rodent models of autoimmune and 
inflammatory diseases [59], and it has been recently hypothesized that they could 
exert a similar action in human disorders. The PPARα agonist fenofibrate reduces the 
expression of interleukin (IL)-17 and IFNγ and improves colitis in IL-10 deficient 
mice, and inhibits the CXCL10 gene expression, repressing the activity of its 
promoter, in TNFα-treated HT (HT)-29 cells [58]. Furthermore, PPARα agonists 
inhibit the secretion of CXCL10 and CCL2 in thyrocytes, suggesting that PPARα is 
implicated in the immune response modulation in AITD [60, 61].  
PPAR ligands act repressing transcriptional activation, via nuclear factor-kB (NF-kB) 
through ligand-dependent transrepression [62]; so, NF-kB is considered a possible 
target to repress the transcription of CXCL10 by PPARα agonists. 	  
MMI has an immunomodulatory effect in GD. Hyperthyroid patients with GD had 
high levels of serum CXCL10, and circulating CXCL10 decreased significantly when 
euthyroidism was reached after MMI therapy. Instead, patients with toxic nodular 
goiter showed a slight, not significant, decrease in the chemokines levels when 
rendered euthyroid by MMI itself. On this base it has been hypothesized that the 
strong reduction in circulating CXCL10 in GD patients treated with MMI therapy is 
related to the immune-modulatory activity of the drug [4].	   Furthermore, MMI has 
been shown to be able to reduce CXCL10 production by thyrocytes, and promotes the 
Th1 to Th2 switch in GD patients [63].	   	  
In recent studies the role of drugs targeting IFNγ dependent chemokines or CXCR3 
has been investigated in several autoimmune disorders. 
CXCL10 has been shown to be involved in the immunopathogenesis of RA. MDX-
1100, “a fully human, anti-IP-10 monoclonal antibody”, has been studied in a phase II 
study [64], in 35 RA patients who did not respond to methotrexate (MTX). The 
response rate was significantly higher in MDX-1100 patients than in the placebo 
group (54% vs 17%). These results suggest that MDX-1100 is well tolerated and 
clinically effective in RA patients. 
BMS-936557, “a fully human, anti-CXCL10 monoclonal antibody”, has been 
investigated in a phase II study [65] in 55 patients with moderately-to-severely active 
ulcerative colitis (UC). The results suggested that BMS-936557 is an effective therapy 
for active UC [64, 65]. 
These studies underline the important efforts that are ongoing in the attempt to find 
new drugs able to block IFNγ dependent chemokines or CXCR3 in autoimmune 
diseases.  
 
New therapies of GO 
 
For many decades corticosteroids (CS) have been used in the therapy of active GO. 
Many studies have shown that steroids decrease orbital congestion and inflammation 
[66]. Pulsed intravenous methylprednisolone (ivMP) has been shown to be more 
effective and is safer than oral prednisone [66]. In a recent large multicenter trial 
ivMP (a cumulative dose of 7.5 g) ameliorated inflammation in about 70% of patients, 
while eye muscle function in 50% of patients [66]. About 20% of GO patients were 
not responsive to the steroids and up to 4% of GO patients experienced disease 
progression or developed compression of the optic nerve within the orbit.  
For these reasons, recently alternative immunosuppressive therapy has been evaluated 
in GO, and more recently, with novel agents that target different antigens involved in 
GO pathophysiology. 
The main targets of these new drugs are the TSH-R and the IGF-1R on the fibroblasts, 
or cytokines and chemokines implicated in various stages of disease progression, or 
immune effector-cells such as B or T cells.  
Rituximab (RTX) 
RTX is a chimeric monoclonal antibody directed against the CD20 protein, present in 
the surface of B cells. RTX destroys B cells and it is used for the therapy of diseases 
characterized by excessive numbers of B-lymphocytes, overactive B-cells, or 
dysfunctional B-lymphocytes. RTX does not destroy antibody-producing plasma cells 
[67], for this reason, antibody production is maintained [67]. RTX has been approved 
by Food and Drug Administration for the therapy of RA, non-Hodgkin’s lymphoma, 
and Wegener’s granulomatosis. RTX is used off-label in different autoimmune 
disorders.  
In humans, clinical trials in RA with RTX have shown it is effective in improving 
symptoms (usually within 8 – 16 weeks); this amelioration persists for the duration of 
B-lymphocytes depletion (typically 16 – 24 weeks) [68].  
The most frequently reported RTX side effects are infusion-related reactions, usually 
occurring at the first infusion [69]. However a recent review of more than 3000 RA 
patients showed that RTX is well tolerated over time. Progressive multifocal 
leukoencephalopathy (PML) has been reported in RTX-treated patients, but mainly in 
patients with SLE, suggesting that SLE may predispose to PML development [70, 
71]. 
The rationale for using RTX in GO is the depletion of B cells to block the production 
of inflammatory cytokines, and of pathogenic autoantibody generation [72]. 
Few reports have suggested that RTX may be effective in GO patients [72, 73]. 
More recently 2 randomized studies have reported contradictory results for the use of 
RTX in GO. Stan et al. [74], to evaluate the efficacy of RTX in GO, designed a 
prospective, randomized, double-masked, placebo-controlled trial. Twenty-five 
patients with GO were enrolled. Two RTX infusions (1000 mg each) (or two saline 
infusions) were given 2 weeks apart. No differences were found in the rate of patients 
showing improvement of clinical activity score (CAS) at 24 weeks (25% placebo; 
31% RTX) or in decrease of CAS at 24 or 52 weeks. There were four adverse events 
(AE) in 3 out of 12 placebo patients and 11 AE in 8 out of 13 RTX-treated patients. 
The Authors suggested that RTX is not effective in GO patients with active and 
moderate to severe GO.  
In another study Salvi et al. [75] conducted a double-blind, randomized trial to 
compare RTX with ivMP in GO patients. Thirty-two patients were randomized to be 
treated with either RTX (2000 or 500 mg) or ivMP (7.5 g). CAS decreased with both 
treatments but more after RTX, whether 1000 mg RTX twice or 500 mg RTX once 
was used. At 24 weeks 100% of RTX patients improved in comparison with 69% 
after ivMP. Disease reactivation was not observed in RTX patients but was present in 
5 after ivMP. Patients treated with RTX showed better motility. The results of this 
trial demonstrate a better therapeutic outcome with RTX in patients with GO, in 
comparison with ivMP.  
Other studies are needed to evaluate RTX in GO patients with different phenotype 
and clinical history. 
 
TSH-R as target 
Small TSH-R molecules have been recently developed as TSH-R agonists (that 
activate the receptor), neutral antagonists (that inhibit the receptor activation by 
agonists), and inverse agonists (that inhibit the activation of receptor by agonists and 
the basal activity) [76]. The effects of a small TSH-R antagonist (NCGC00229600) 
[77] in GO orbital fibroblasts or adipocytes, on adenylate cyclase or 
phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B signaling, has been 
tested, demonstrating that inhibits the ligation of TSH-R on orbital fibroblasts and the 
accumulation of hyaluronic acid in the orbit, and suggesting that similar molecules 
with increased potency may be effective in the future for GO [78].	   	  
IGF-1 receptor as target 
Orbital fibroblasts coexpress IGF-1R with the TSH-R in patients with GO [79]. 
Teprotumumab (RV 001, R1507) is a human monoclonal antibody that binds to the 
extracellular IGF-R1 domain designed for the treatment of hematologic and solid 
hematologic tumors [80]. Teprotumumab has been very recently demonstrated to 
reduce cell proliferation in GO fibrocytes [80] and it is currently used in a phase II 
randomized clinical trial in patients with active GO, to be completed in 2016 [81]. 
TNFα as target 
TNFα has been shown to be important in many autoimmune disorders and in GO [8]. 
Etanercept is a fusion protein (produced by recombinant DNA) that fuses the TNF 
receptor to the constant end of IgG1. It is a large molecule (150 kDa) that binds to 
TNFα and inhibits its role in inflammatory diseases, including autoimmune diseases 
such as ankylosing spondylitis, RA, psoriasis, psoriatic arthritis, sarcoidosis, and in 
others [82].  
Paridaens et al. [83] have used etanercept for the therapy of 10 patients with active 
GO showing inactivation of the disease in 6. Other studies are needed to evaluate it in 
comparison with ivMP.  
 
IL-6 as target 
 
IL-6 acts as a pro-inflammatory cytokine, and it is secreted by T cells and 
macrophages to stimulate immune response, e.g. during inflammatory diseases and 
infections. 
The IL-6 and the soluble IL-6 receptor have been demonstrated to be activated in GO, 
and elevated circulating soluble IL-6 receptor concentrations have been shown in 
patients with active GO [84]. 
Many studies have been devoted to develop anti-IL-6 agents as therapy against many 
of inflammatory diseases. Tocilizumab is a humanized monoclonal antibody against 
the IL-6 receptor, which has been approved for RA [85], Castleman's disease and 
systemic juvenile idiopathic arthritis [86].  
Recently a prospective nonrandomized study in 18 GO patients (resistant to previous 
corticosteroids) with tocilizumab has been conducted. Thirteen patients reduced 
proptosis, fifteen patients had an amelioration in extraocular motility, and 7/13 
patients resolved their diplopia. No relapse of GO were observed at the end of the 
follow up. This study suggests that tocilizumab may be effective in the therapy of 
patients with GO refractory to steroids [87]. 
 
Th1 Chemokines in GO and as a possible target 
 
GO is clinically evident in about 50% of GD patients, and in 3-5% with severe forms. 
According to what reported above, a Th1-dominance could prevail in the initial active 
phase of GD, during which high levels of circulating CXCL10 are present. In fact 
orbitopathy may be T cell mediated and all the antibodies identified secondary to 
a reaction involving cytotoxic T cells [88].  
The role of T cell mediated cytotoxicity in GO has been postulated [89]. 
Circulating CXCL10 are significantly higher in GO patients in the active phase of the 
disease than in the inactive one. Primary cell cultures of retrobulbar fibroblasts and 
preadipocytes obtained from GO patients did not secrete CXCL10 in basal conditions; 
however IFNγ alone induces a dose-dependent secretion of IFNγ dependent 
chemokines by orbital cells, and this secretion is enhanced by TNFα. These results 
suggest that GO retrobulbar cell types take part in the self-perpetuation of 
inflammation secreting chemokines, once stimulated by cytokines [45]. The 
chemokines secreted by orbital cells enter the circulation explaining why circulating 
Th1 chemokines are significantly higher in GO patients in the active phase of the 
disorder. Other studies confirmed that GD patients with ophthalmopathy had 
significantly higher circulating CXCL10 than GD patients without GO [4]. In a recent 
study to evaluate the importance of circulating CXCL9 and CXCL10 in GO activity, 
42 subjects were subdivided into 4 groups [90]. The first group was composed by 15 
euthyroid patients with clinical symptoms of orbitopathy in therapy with CS 
[infusions of ivMP and teleradiotherapy (TR)]. The second group comprised 10 
hyperthyroid GD patients; the third 10 patients with GD in euthyroidism; and the 
fourth 7 controls age- and sex-matched to groups 1-3. Serum CXCL9 and CXCL10 
levels significantly reduced during CS and TR treatment in GO patients, suggesting 
that the elevated levels of these chemokines are linked to the activity of orbital 
inflammation. CXCL9 and CXCL10 may serve as guide in the therapeutic decision-
making in GO patients [90]. These findings were more recently confirmed in another 
study that demonstrated a reduction of CXCL10 in patients treated with intravenous 
CS [91]. 	  
PPARγ activator rosiglitazone (0.1–10 µM) reduces dose-dependently the secretion of 
CXCL9, -10, -11 in orbital fibroblasts, and preadipocytes, suggesting PPARγ-agonists 
modulate CXCR3 chemokines [45, 47]. The possibility that PPARγ-agonists exert 
anti-inflammatory action, without expanding the retrobulbar fat, in GO needs further 
studies [92]. 
PPARα ligands have shown therapeutic action in animal models of autoimmune and 
inflammatory diseases. In humans the PPARα agonists fenofibrate, gemfibrozil, 
ciprofibrate inhibit the secretion of CXCL10 and CCL2 in orbital fibroblasts, and 
preadipocytes, suggesting that PPARα is implicated in the immune response 
modulation in GO [60, 61].  
Other studies with drugs targeting IFNγ dependent chemokines or CXCR3 are needed 
in GO. 
 
Conclusion 
 
Th1 lymphocytes are very important in the autoimmune process, such as IFNγ and the 
IFNγ dependent chemokines. CXCR3 and its IFNγ dependent chemokines (CXCL10, 
CXCL9, CXCL11) are important in the immune-pathogenesis of autoimmune 
thyroiditis (AT), Graves Ophthalmopathy (GO), and Graves disease (GD).  
Attempts have been made to modulate the autoimmune process in AITD. Peroxisome 
proliferator-activated receptor (PPAR)γ or -α agonists exert a modulatory role on 
CXCR3 chemokines in autoimmune thyroid disorders. Also methimazole has an 
immune-modulatory effect on CXCR3 and its chemokines in GD. Corticosteroids 
have been shown to inhibit the production of IFNγ and the IFNγ dependent 
chemokines in AITD, too. Other studies are ongoing to evaluate the use of new 
molecules antagonists of CXCR3, or that block CXCL10, in Hashimoto thyroiditis 
(HT), GD and GO. 
In recent years, novel molecules which target the different agents involved in the 
immune-pathogenesis of GO have been proposed as an alternative to corticosteroids. 
A randomized trial with rituximab suggests good efficacy in patients with active GO. 
However discordant results have been reported, too. Promising results have been 
observed with small antagonists of TSH-R molecules (that interact with the receptor 
in thyrocytes and fibroblasts), with the anti-IGF-1 receptor monoclonal antibody 
teprotumumab, and with tocilizumab (an antibody anti-soluble IL-6 receptor) in GO. 
However, randomized and controlled studies are needed to generalize these 
interesting results. 
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